FOSUN PHARMA

The stock declined 0.31% to close at HK$16.15 after falling to HK$15.99 in the morning session and subsequently recovering in afternoon trading, reflecting mixed market sentiment on the company's fundamentals. Q1 2026 results demonstrated robust operational momentum with revenue of HK$11.42 billion (+13.2% YoY), net profit of HK$987 million (+20.54% YoY), and EPS of HK$0.3741 (+20.46% YoY), while operating profit surged 33.1% YoY and net margin expanded to 8.64%. Despite this earnings strength, the stock has fallen 19.05% year-to-date and retreated 44.31% from its 52-week high of HK$29, trading at a depressed valuation of 0.77x book value. Although the PE ratio of 10.91 appears attractive, investor confidence in a near-term valuation recovery appears restrained.

Shanghai Fosun Pharmaceutical rose 0.81% to HKD 16.20 today, supported by robust first-quarter earnings growth and advancing clinical development programs at subsidiary companies. Q1 revenue of HKD 11.42 billion grew 13.2% year-over-year, with net profit reaching HKD 987 million up 20.54% yoy; Fosun Pharma Shenzhen received China's regulatory approval to commence Phase I trials for FXR0906, a therapeutic candidate for hypertriglyceridemia, while subsidiary financing initiatives such as Fosun Antengene's capital increase are progressing steadily. However, the stock remains 44.14% below its mid-September 2025 high of HKD 29 and has slipped 18.8% year-to-date from HKD 19.95, suggesting investors remain cautious about the company's growth outlook; while current valuations appear attractive at 10.94x P/E and 0.77x P/B, the market seems to be awaiting evidence that the group can transform its reported earnings growth into sustained stock price appreciation.

Fosun Pharma (2196.HK) closed at HKD 16.07, down 2.4% from the previous close of HKD 16.47, after hitting an intraday low of HKD 15.92 in the afternoon session. The morning session opened at HKD 16.37 and slid downward; afternoon weakness persisted, reflecting broad selling pressure. Recent catalysts remain supportive — subsidiary Virax Biolabs inked a multi-country commercial supply agreement with Fosun Diagnostics, and Fosun Pharma Shenzhen secured approval to initiate Phase I trials for FXR0906 targeting hypertriglyceridemia. However, HSBC analysts maintained a 'Hold' rating, possibly capping upside momentum. Financially, Q1 2026 revenue reached HKD 11.42B (+13.2% year-over-year), net profit HKD 987M (+20.5% YoY), and EPS HKD 0.374 (+18.3% YoY), signaling robust earnings growth. Valuation metrics appear attractive at PE 10.85x and PB 0.77x. The stock faces structural headwinds: year-to-date decline of -19.45%, down 44.6% from the September 2025 52-week high of HKD 29, having recovered only 7.85% from the June 2026 52-week low of HKD 14.90. The current price sits materially below both the 20-day MA (HKD 16.26) and 60-day MA (HKD 16.98), signaling downward momentum. Low turnover of 0.35% suggests muted investor interest.

Fosun Pharma closed at HK$16.47, modestly higher than the previous close, as morning weakness from the intraday low of HK$16.29 was gradually recovered during the afternoon session, with an intraday range of 1.78% reflecting limited but easing selling pressure on the stock. Recent developments remain constructive: Fosun Diagnostics secured multi-country commercial supply partnerships with Virax Biolabs, subsidiary Fosun Antengene completed a capital raise of approximately RMB 1 billion, Fosun Adgenvax filed for Hong Kong IPO listing, and regulatory approval was granted for Luvometinib in new indications, showcasing the group's diversified biotech pipeline; on the earnings front, Q1 2026 EPS reached HK$0.3741, up 20.46% year-over-year, with revenue of HK$11.42 billion growing 13.2% YoY and net margin expanding to 8.64%, demonstrating accelerating profitability. However, the stock has declined 17.44% year-to-date and is down 43.21% from its 52-week high of HK$29, trading below the 60-day moving average at HK$17.036; despite attractive valuations at PE of 11.12 and PB of 0.79, the market continues to absorb prior valuation compression.

Shanghai Fosun Pharmaceutical (HK$2,196) closed slightly lower at HK$16.46, continuing consolidation. Recent ecosystem partnerships within the group—including Virax Biolabs' supply deal with Fosun Diagnostics across Southeast Asia and Fosun Adgenvax's Hong Kong IPO filing—signal active portfolio optimization, though market attention remains distributed. Fundamentals provide steady support: Q1 revenue of HK$11.42 billion rose 13.2% year-over-year, net profit surged 20.54% to HK$987 million, and EPS of HK$0.3741 increased 20.46% YoY, with net margin climbing to 8.65%. The stock has declined 17.49% year-to-date and trades 43% below its 52-week high of HK$29. Trading at a P/E of just 11× and P/B of 0.79×, valuation remains undemanding. The market appears to be reconciling steady earnings growth against uncertainty over the long-term value unlocking from asset restructuring.